Epirubicin Cyclosporine

Other drugs almokalant, carvedilol, carbamazepine (N-glucuronidation), clonixin, cyclosporin A, epirubicin, ezetimibe, Maxipost, tacrolimus... 

Acyclovir Erythromycin Ivermectin Itraconazole Rifampin Actinomycin D Daunorubicin Doxorubicin Docetaxel Epirubicin Etoposide Imatinib Irinotecan Paclitaxel Vinblastine Vincristine Amprenavir Indinavir Nelfinavir Ritonavir Saquinavir Cyclosporine A Tacrolimus Digoxin Quinidine Verapamil Diltiazem Aldosterone Cortisol Corticosterone Dexamethasone Hydrocortisone Cyclosporine Metkephamid Enkephalin... 

Some studies reported that polyoxyethylene (POE) stearates (under the brand name Myrj) and alkyl-polyethyleneoxide (PEO) surfactants (under the brand name Brij) can inhibit efflux pumps. The oral bioavailability of the P-gp substrate cyclosporine A administered in a solid dispersion of polyoxyethylene 40 stearate (Myrj 52) was in the same range as the oral bioavailability of the commercial product Sandimmune Neoral (Liu et al. 2006). In a study by Lo, it has been shown that apical to basolateral epirubicin transport across Caco-2 cells was enhanced in the presence of polyoxyethylene 40 stearate and the basolateral to apical transport was decreased. These results indicate that polyoxyethylene stearates effect efflux pumps (Lo 2003). Similar results were gained when using polyoxyethylene laurylether (Brij 30). In another study, tablets based on polyoxyethylene 40 stearate containing the P-gp substrate rhodamine 123 increased the oral bioavailability in rats by about 2.4-fold (Foger et al. 2006a). 

Clinically important, potentially hazardous interactions with alfuzosin, amiodarone, aprepitant, carbamazepine, celiprolol, corticosteroids, cyclosporine, epirubicin, erythromycin, mistletoe, moricizine, oxprenolol, ranolazine, simvastatin, sulpiride... 

Clinically important, potentially hazardous interactions with cyclosporine, epirubicin, grapefruit juice, imatinib, ketoconazole... 

Eggert J, Scheulen ME, Schiitte J, Budach W, Annweiler HM, Mengelkolch B, Skorzec M, Wiefelspiitz J, Sack H, Seeber S. Influence of cyclosporin A on the pharmacokinetics and pharmacodynamics of doxorubicin and epirubicin, Am Hematol (1994) 68, A26. 

---